|Targets||Sphingosine 1 Phosphate Receptor|
|Description||JTE 013 has been found to be an antagonist of Sphingosine-1-Phosphate Receptor-2 (S1P2R).|
|Purity||≥98% by HPLC|
|Synonyms||JTE 013; JTE013; JTE-013; 1-[1,3-Dimethyl-4-(2-methylethyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-4-(3,5-dichloro-4-pyridinyl)-semicarbazide; N-(2,6-Dichloro-4-pyridinyl)-2-[1,3-dimethyl-4-(1-methylethyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]hydrazinecarboxamide|
CYM 50260 has been found to be a S1P4 agonist.
CS-0777 is a selective sphingosine 1-phosphate receptor modulator agonist. It is in clinical trials for the treatment of multiple sclerosis, but no recent devel...
Ozanimod, also known as RPC1063, is a selective oral S1P Receptor 1 modulator.
The hydrochloride salt form of PF-543, a novel SphK1 inhibitor that could exhibit activity in induceing necrosis in human colorectal cancer cells in biological ...
This active molecular is a selective S1P1 receptor agonist that originated by Bristol-Myers Squibb. BMS-520 shows really good efficacy in animal models of arthr...
This active molecular is a S1P1/S1P5 agonist with limited activity at S1P3. AMG 369 has no activity at S1P2 and S1P4. AMG-369 is shown to reduce blood lymphocyt...
CYM 50308 has been found to be an effective and selective S1P4 agonist.
The hydrochloride salt form of CYM 50358, which has been found to be an effective S1P4 antagonist.